LAVAL, Quebec, Nov. 20, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that the Company will be hosting an Investor Day on December 16, 2015, from 8:00 a.m. ET to 12:30 p.m. ET, where the Company will be providing updated financial guidance, discussing certain business operations and highlighting certain R&D programs.
Conference Call and Webcast Information
The dial-in number to participate on this call is (877) 876-8393, confirmation code 86470820. International callers should dial (973) 200-3961, confirmation code 86470820. A replay will be available following the conclusion of the conference call through December 23, 2015, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 86470820.
The webcast and slide presentation will be hosted in the investor relations section of its corporate website at www.valeant.com. Participants should allow approximately five to ten minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
This press release may contain forward-looking statements, including, but not limited to, statements regarding Valeant's intent to hold an Investor Day, provide updated financial guidance, discuss certain business operations and highlight certain R&D programs. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
Contact Information: Laurie W. Little 949-461-6002 email@example.com
Elif McDonald 905-695-7607 firstname.lastname@example.org
SOURCE Valeant Pharmaceuticals International, Inc.